Archive for the ‘Coeliac Research Fund Partners’ Category

We are grateful Coles Supermarkets are supporting coeliac disease in a big way by partnering with the CRF to raise awareness of the condition.  Their partnership will help us achieve greater awareness during Coeliac Awareness Week (March 13-20) and provide profile for the CRF in their advertising and at the Gluten Free Expos they support throughout the year.

Coles are our Principal Campaign Partners of Coeliac Awareness 2010-2011.

Coles have a large range of gluten free products to assist in following a strict gluten free diet. From Pantry essentials to indulgent treats, we are constantly improving our range to deliver a variety of delicious gluten free alternatives located in the Freezer, Bakery and Health Food aisles of your local Coles Supermarket.

Click here to go to the Coles Supermarket’s website

Click here for the new Gluten Free Page on the Coles website

Nexpep is an early stage biotechnology company focused on developing a treatment for coeliac disease and a set of diagnostic and monitoring tools to manage patient health.   Nexpep’s treatment is a desensitisation therapy using a series of peptides which target the different genetic forms of coeliac disease. This peptide based immunotherapy is designed to desensitise the patient’s immune system to gluten toxic peptides.

This treatment approach to an immune disease is not unique, and there is sufficient evidence of desensitisation in other disorders. This approach may lead Nexpep to expand it’s development into therapies for other autoimmune disorders in the future.  Nexpep is in a unique position, holding the relevant patents to diagnostics and treatments utilising the gluten peptides recognised by T cells in coeliac disease. No other group or company is pursuing peptide immunotherapy for coeliac disease.

Nexpep’s main product, Nexvax2, is a unique immune-focussed therapy for coeliac disease. The aim of Nexvax2 is to desensitise a coeliac disease patient’s immune system to gluten so that a state of “gluten tolerance” is achieved - analagous to traditional desensitisation regimens for several allergic diseases. Nexvax2 is comprised of select gluten fragments called peptides, and it is envisaged that Nexvax2 would be administered as a series of injections. A study to test the safety of Nexvax2 (phase 1 trial) is well underway (see: http://clinicaltrials.gov/ct2/show/NCT00879749), with results expected in the middle of 2010. The main aim of this early trial is to determine the safety of Nexvax2 in people with coeliac disease. Additional studies will be performed on Nexvax2 to establish the optimal dose and how effective it is.

As more information becomes available it will be posted on our website. If you would like more information about Nexpep Pty Ltd please contact Nexpep CEO Dr Bob Anderson. Visit our website http://www.nexpep.com

Nexpep’s research and development program was performed at The Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, Australia, under a collaborative research agreement between Nexpep, WEHI and the Royal Melbourne Hospital / Melbourne Health.

Inova Diagnostics and The Werfen Group supported the visit of Professor Markku Mäki to Australia for Coeliac Awareness Week 2010.

Inova Diagnostics and The Werfen Group, in association Integrated Sciences, realised the importance of a visit by a world leader in coeliac disease research to Australia. 

Inova is one of the world leaders in autoimmune disease diagnostics

INOVA is dedicated exclusively to autoimmune diagnostics. They offer quality on a comprehensive range of autoimmune testing reagents  and provide technical proficiency, product support and service to their customers.

A History of innovation

INOVA Diagnostics, Inc. was formed in 1987 by a group of scientists who were directly involved in the early development of autoimmune disease serology as well as the people responsible for the first commercially available autoantibody test kits. INOVA Diagnostics has a rich history of innovative and first FDA-cleared products focused on the diagnosis of autoimmune diseases such as coeliac disease, rheumatoid arthritis, and systemic lupus erythematosus among others.

In July 2009, Werfen Group successfully completed the acquisition of the autoimmune disease diagnostics business of The Binding Site Group Ltd.  The Binding Site autoimmune disease test portfolio complements the INOVA Diagnostics’ family of products and nearly doubles the total portfolio to over 400 products and systems.

Today, INOVA is recognized worldwide as a leader in autoimmune disease diagnostics. The majority of their products are produced in their Scripps Ranch facility located in the heart of Southern California’s Biotechnology community. They combine administration, R&D and manufacturing under one roof, which provides reliable and economical solutions  for all of their autoimmune disease testing needs.

Visit their website: http://www.inovadx.com

Integrated Sciences supported the visit of Professor Markku Mäki to Australia for Coeliac Awareness Week 2010.

The visit of Professor Mäki would not have been possible without the generous support of Integrated Sciences (and Inova).  Their understanding of the coeliac disease landscape has made possible a visit by a world leader in coeliac disease research to Australia and is a very important milestone.  It means we are serious about making a difference.  Integrated Sciences is partnering the CRF in our vision and we know they are as committed as we are to changing outcomes for those with coeliac disease, both diagnosed and undiagnosed.

Integrated Sciences Pty Ltd, established 1983 is an Australian owned business that supplies both the Australian Diagnostics and Life Science markets. Their staff are scientifically qualified and embrace the organisations’s values of integrity and excellence in all they do. Integrated Sciences has welcomed being affiliated with Coeliac Awareness Week through their representation of the INOVA Diagnostics/Werfen products. INOVA Diagnostics is a recognised worldwide leader in autoimmune disease diagnostics with particular interest in the importance of correct serological diagnosis of Coeliac Disease & ongoing serological maintenance. Their highly rapid and specific Coeliac diagnostic kits provide non-invasive diagnosis and disease monitoring.

It is absolutely critical that this disease is diagnosed and managed correctly through consultation with your physician.

 Click here to go to the Integrated Sciences website.

With every sale of ‘the real bread mix’ Springhill proudly makes a donation to the CRF.  Sprnghill believes that the work CRF is undertaking in research and education of coeliac disease is vital to the progression of awareness and ultimately a cure.

The CRF very much appreciates the ongoing support of Springhill in not only raising funding to support the work we are doing, but helping increase our profile by including the CRF logo on their ‘real bread mix’.

Springhill is a family owned and operated business based in regional Victoria.  The company was born out of a passion for creating food that people love to enjoy.  Their products are handmade and cut with a great deal attention to quality. 

Springhill believes that those with dietary considerations should still enjoy great tasting food.  Their gluten free range includes a variety of slices, rocky roads, biscuits and ‘the real bread mix’.  The real bread mix is a product which takes a new look at gluten free bread, with the inclusion of nutritious and delicious ingredients such as pea protein, flaxseed flour and psyllium. 

Find out more about Springfarm gluten free products at http://www.springhillfarm.com.au

Astrazenca has supported the CRF in the production of an informative category 1 CD about coeliac disease which can be obtained from the CRF upon request.  The CD provides a valuable educational tool for GPs, health professionals and those wishing to understand the condition.

During the visit of Markku Mäki to Australia in March 2010, Astrazeneca partnered with the CRF to provide a series of seminars to gastroenterologists and experts in the field of coeliac disease.

As one of the world’s leading pharmaceutical companies, Astrazeneca focuses on discovery, knowledge and life - turning good ideas into innovative, effective medicines for important areas of healthcare.AstraZeneca Australia exports pharmaceutical products from its Sydney plant, to more than 30 countries around the world  from Europe to Asia, New Zealand to Japan.

The Coeliac Society aims to enhance the quality of life of people requiring a gluten free diet for life and to encourage and support research towards a cure or other ethical forms of treatment. The Society provides information and support to those diagnosed with coeliac disease or another medical need for a gluten free diet.

 Through membership of your state Coeliac Society, information is available about the gluten free diet, ingredients, where to buy gluten free food, recipes and cooking, eating out, overseas travel and research. Activities such as information seminars, cooking demonstrations, shopping tours, gluten free food expos and children’s events may be held. In various areas, volunteer contact people provide a local support network for members in their region.

For information about membership, phone your state Society on 1300 458 836 or visit www.coeliacsociety.com.au